Suppr超能文献

贝伐珠单抗治疗恶性脑肿瘤放射性坏死复发 2 例报告

Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases.

机构信息

Department of Neurosurgery, Osaka Medical College, 2-7, Daigakumachi, Takatsuki, Osaka 569-8686, Japan.

出版信息

J Neurooncol. 2011 May;102(3):471-5. doi: 10.1007/s11060-010-0333-3. Epub 2010 Aug 7.

Abstract

Bevacizumab is expected to constitute a new treatment modality for radiation necrosis. In the present cases, we observed a recurrence of radiation necrosis after temporary improvement by bevacizumab treatment. Re-treatment with bevacizumab controlled the necrosis again. A 39-year-old male and a 57-year-old female were diagnosed with glioblastoma and lung cancer metastasis, respectively. The former patient underwent partial resection of the glioblastoma, followed by boron neutron capture therapy (BNCT) and 30 Gy of fractionated X-ray radiotherapy. Eleven months after BNCT, he suffered from left hemiparesis and convulsions with enlargement of a perifocal edema. The latter patient underwent stereotactic radiosurgery twice for the same tumor. Three months after the second radiosurgery, she had an uncontrollable convulsion and right hemiplegia with a massive perifocal edema. Both lesions were suggested to be radiation necroses by positron emission tomography using amino acids as a tracer. Neither patient responded to corticosteroids, anticoagulants, or vitamin E. They underwent treatment with 5 mg/kg bevacizumab biweekly, for a total of 6 cycles. The size of the perifocal edema was clearly reduced in response to the treatments. The neurological status of the patients improved concomitant with therapy. However, the clinical status of both patients was aggravated several months after the bevacizumab was stopped, and the perifocal edemas enlarged again. The patients underwent a second treatment with bevacizumab, and the perifocal edemas again decreased. Although radiation necrosis may recur several months after bevacizumab treatment, repeated bevacizumab treatments also appear to be effective.

摘要

贝伐珠单抗有望成为治疗放射性坏死的一种新方法。在本病例中,我们观察到贝伐珠单抗治疗后暂时改善的放射性坏死再次复发。再次用贝伐珠单抗治疗控制了坏死。一名 39 岁男性和一名 57 岁女性分别被诊断患有胶质母细胞瘤和肺癌转移。前者患者接受了部分胶质母细胞瘤切除术,随后接受硼中子俘获治疗(BNCT)和 30Gy 的分割 X 射线放疗。BNCT 后 11 个月,他出现左半身瘫痪和抽搐,伴有周围水肿扩大。后者患者因同一肿瘤接受了两次立体定向放射外科手术。第二次放射外科手术后 3 个月,她出现无法控制的抽搐和右侧偏瘫,伴有大量周围水肿。两者病变均通过使用氨基酸作为示踪剂的正电子发射断层扫描提示为放射性坏死。两种病变对皮质类固醇、抗凝剂或维生素 E 均无反应。他们接受了 5mg/kg 贝伐珠单抗每两周一次的治疗,共 6 个周期。治疗后周围水肿的大小明显缩小。患者的神经功能状态随着治疗而改善。然而,贝伐珠单抗停药几个月后,患者的临床状况恶化,周围水肿再次扩大。患者接受了第二次贝伐珠单抗治疗,周围水肿再次减少。尽管贝伐珠单抗治疗后放射性坏死可能会复发,但重复贝伐珠单抗治疗似乎也是有效的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验